Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NovoTTF-100L + pemetrexed
- Development stage
- Unknown
- Lead developer
- NovoCure
- Modality
- Small Molecules
- Administration
- Transdermal (device), Intravenous (pemetrexed)
01
Overview
This is a combination therapy consisting of the **NovoTTF-100L System** (also called Optune Lua), a non-invasive medical device delivering Tumor Treating Fields (TTFields), used alongside the **antifolate chemotherapy drug pemetrexed** (plus a platinum-based agent such as cisplatin or carboplatin) for the first-line treatment of **unresectable, locally advanced or metastatic malignant pleural mesothelioma**. The NovoTTF-100L System works by producing low-intensity, intermediate-frequency alternating electric fields that disrupt mitosis and inhibit cancer cell proliferation, while pemetrexed inhibits folate-dependent enzymes essential for DNA and RNA synthesis, further blocking tumor cell replication. This combination has shown improved survival outcomes in clinical trials such as STELLAR, leading to regulatory approvals in both the US and Europe for this specific indication[1][2][3][5].
- Brand names
- Optune Lua
- Other names
- Tumor Treating Fields (TTFields) plus pemetrexed
02
Targets
DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on NovoTTF-100L + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovoTTF-100L + pemetrexed.